Baird Assumes Trius Therapeutics (TSRX) at Outperform

Baird assumes coverage on Trius Therapeutics (NASDAQ: TSRX) with a Outperform rating and $11 price target.

The firm comments, "Value-creating catalysts are now drawing closer and we think TSRX's tedizolid Phase III program is already de-risked to a good degree. Early signs of product differentiation are emerging and more call options remain in the pipeline. We find TSRX very attractive at these levels, and think some exposure to this name is warranted for small-cap focused healthcare investors."

For an analyst ratings summary and ratings history on Trius Therapeutics click here. For more ratings news on Trius Therapeutics click here.

Shares of Trius Therapeutics closed at $5.41 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies Starts Aditya Birla Real Estate (ABREL:IN) at Buy
• Keefe, Bruyette & Woods Starts Columbia Financial Inc (CLBK) at Outperform
• Jefferies Starts Freenome Inc. (FRNM) at Buy